Boehringer Enhances Diabetes Pipeline With Zealand's GLP-1/Glucagon Agonist
This article was originally published in The Pink Sheet Daily
Executive Summary
Boehringer wins global rights to Zealand's Phase I-ready novel diabetes compound, pledging €20 million during 2011.